EMPOWER: Optimizing the Paradigm Shift Driven by CDK 4/6 Inhibition in Metastatic HR-Positive, HER2-Negative Breast Cancer

Thursday, April 9, 2020

6:00 – 8:00 PM CDT

07:00 PM Eastern; 06:00 PM Central; 05:00 PM Mountain; 04:00 PM Pacific

Activity Description

This program will review the use of CDK 4/6 inhibitors in the treatment of HR+/HER2-negative breast cancer and the management of treatment-related adverse events.

Target Audience

This CME initiative is designed to meet the educational needs of medical oncologists, advanced practice clinicians, oncology nurses, pharmacists, and other healthcare providers involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Educational Objectives

Upon the completion of this program, attendees should be able to:

  • Identify the patient who will benefit from CDK 4/6 inhibitor therapy with consideration of patient and disease characteristics and appropriately time its use in the course of the disease
  • Recognize commonly associated toxicities of CDK4/6 inhibition, and apply strategies for both the monitoring and management of adverse events associated with their use in patients with metastatic breast cancer
  • Utilize methodologies to activate all members of the healthcare team, encourage collaboration, and incorporate shared decision-making and survivorship tools to assist in optimizing patient outcomes and management of adverse events

Disclosure of Conflicts of Interest

Dr. Hurvitz reports editorial support and research grants paid to UCLA: Ambrx, Amgen, Bayer, Daiichi Sankyo, GNE/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Dignitana.

Dr. O’Shaughnessy received honoraria for consulting and advisory boards for AbbVie Inc., Agendia, Amgen Biotechnology, AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Eisai, Genentech, Genomic Health GRAIL, Immunomedics, Heron Therapeautics, Ipsen Biopharmaceuticals, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Ondonate Therapeutics, Pfizer, Puma Biotechnology, Prime Oncology, Roche, Seattle Genetics, Syndax Pharmaceuticals, and Takeda.

Dr. Aithal is a member of Speakers Bureaus for Pfizer, Novartis, and PUMA.

Dr. Rao serves as a consultant for Novartis, Genentech, PUMA, and Genomic Health.

Planners and Managers

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator, has nothing to disclose.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Purpose: This program would be beneficial for nurses involved in the treatment of patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Credits: 2.0 ANCC Contact Hour.

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hour of continuing nursing education of RNs and APNs.



Disclosure of Unlabeled Use

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.


Med Learning Group makes every effort to develop CME activities that are science based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this live activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

Contact Information for Questions About the Activity


System Requirements

Performedia requires a modern web browser (Microsoft Edge, Mozilla Firefox, Apple Safari, Google Chrome). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software.

Release date: April 9, 2020
Expiration date: April 9, 2020
Estimated time to completion: 2.0 hours